Nanjing Vazyme Biotech Co Ltd Asset Resilience Ratio
Nanjing Vazyme Biotech Co Ltd asset resilience ratio. Nanjing Vazyme Biotech Co Ltd (688105) has an Asset Resilience Ratio of 45.03% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688105 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nanjing Vazyme Biotech Co Ltd (2019–2025)
Asset resilience ratio of Nanjing Vazyme Biotech Co Ltd from 2019 to 2025. This chart shows how Nanjing Vazyme Biotech Co Ltd's Asset Resilience Ratio has changed over time. Read Nanjing Vazyme Biotech Co Ltd (688105) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nanjing Vazyme Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Nanjing Vazyme Biotech Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.09 Billion | 45.03% |
| Total Liquid Assets | CN¥2.09 Billion | 45.03% |
Asset Resilience Insights
- Very High Liquidity: Nanjing Vazyme Biotech Co Ltd maintains exceptional liquid asset reserves at 45.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nanjing Vazyme Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nanjing Vazyme Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Nanjing Vazyme Biotech Co Ltd Asset Resilience Ratio by Year (2019–2025)
Nanjing Vazyme Biotech Co Ltd asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Nanjing Vazyme Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 40.76% | CN¥2.05 Billion ≈ $299.86 Million |
CN¥5.03 Billion ≈ $735.75 Million |
-3.26pp |
| 2024-12-31 | 44.01% | CN¥2.22 Billion ≈ $325.15 Million |
CN¥5.05 Billion ≈ $738.78 Million |
+17.66pp |
| 2023-12-31 | 26.35% | CN¥1.51 Billion ≈ $221.55 Million |
CN¥5.75 Billion ≈ $840.85 Million |
-2.28pp |
| 2022-12-31 | 28.63% | CN¥1.72 Billion ≈ $251.58 Million |
CN¥6.01 Billion ≈ $878.75 Million |
-14.26pp |
| 2021-12-31 | 42.89% | CN¥1.98 Billion ≈ $289.13 Million |
CN¥4.61 Billion ≈ $674.17 Million |
-6.48pp |
| 2020-12-31 | 49.37% | CN¥795.65 Million ≈ $116.43 Million |
CN¥1.61 Billion ≈ $235.83 Million |
+49.35pp |
| 2019-12-31 | 0.02% | CN¥50.00K ≈ $7.32K |
CN¥324.33 Million ≈ $47.46 Million |
-- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more